European Respiratory Society Monograph, Vol. 68. 2015
ISBN (electronic): 9781849840620
DOI: 10.1183/2312508X.erm6815
Lung cancer is the most common cause of death from cancer worldwide – it is estimated to cause nearly one in five cancer deaths. Most lung cancer patients are diagnosed late and for many of them, there are currently no curative therapy options available, meaning long-term survival is still low. Nevertheless, enormous progress has been made in the field during the last decade. This Monograph provides a comprehensive overview of the current knowledge of and advances in lung cancer, covering areas such as: screening; tobacco control; COPD; diagnosis; therapy; and treatment of early stage lung cancer from both a surgeon's and radiation oncologist's perspective. Very recent achievements in innovative fields, such as targeted therapies and immunotherapies, are also discussed.
Preface Tobias Welte Eur Respir Monogr 2015; 68: vii-viii | |
Guest Editors
Eur Respir Monogr 2015; 68: ix-xi | |
Introduction Martin Reck, Anne-Marie C. Dingemans, Virginie Westeel Eur Respir Monogr 2015; 68: xiii | |
List of abbreviations
Eur Respir Monogr 2015; 68: xiv | |
Epidemiology: development and perspectives Georgia Hardavella, Tariq Sethi Eur Respir Monogr 2015; 68: 1-11 | |
Screening John K. Field, Anand Devaraj, Stephen W. Duffy, David R. Baldwin Eur Respir Monogr 2015; 68: 12-23 | |
Tobacco control Thierry Urban, Michel Underner, José Hureaux, Xavier Quantin Eur Respir Monogr 2015; 68: 24-37 | |
The association with COPD Juan P. de-Torres, Javier J. Zulueta Eur Respir Monogr 2015; 68: 38-49 | |
Idiopathic pulmonary fibrosis Carlos Robalo Cordeiro, Tiago M. Alfaro, Sara Freitas, Jessica Cemlyn-Jones Eur Respir Monogr 2015; 68: 50-63 | |
Histological diagnosis: recent developments Gavin M. Laing, Andrea D. Chapman, Louise M. Smart, Keith M. Kerr Eur Respir Monogr 2015; 68: 64-78 | |
The current and future roles of genomics Kwun M. Fong, Marissa Daniels, Felicia Goh, Ian A. Yang, Rayleen V. Bowman Eur Respir Monogr 2015; 68: 79-94 | |
Molecular pathology Florian Laenger, Nicolas Dickgreber, Ulrich Lehmann Eur Respir Monogr 2015; 68: 95-118 | |
Adequate tissue for adequate diagnosis: what do we really need? Guido M.J.M. Roemen, Axel zur Hausen, Ernst Jan M. Speel Eur Respir Monogr 2015; 68: 119-135 | |
Management of early stage lung cancer: a surgeon's perspective Pascal A. Thomas Eur Respir Monogr 2015; 68: 136-147 | |
Management of early stage lung cancer: a radiation oncologist's perspective Esther G.C. Troost, Krista C.J. Wink, Jaap D. Zindler, Dirk De Ruysscher Eur Respir Monogr 2015; 68: 148-158 | |
Mediastinal staging Christophe Dooms, Herbert Decaluwe, Paul De Leyn Eur Respir Monogr 2015; 68: 159-166 | |
Approaches in patients with locally advanced NSCLC: a surgeon's perspective Paul E. Van Schil, Michèle De Waele, Jeroen M. Hendriks, Patrick R. Lauwers Eur Respir Monogr 2015; 68: 167-177 | |
Approaches in patients with locally advanced NSCLC: a radiation oncologist's perspective Dirk De Ruysscher, Stéphanie Peeters, Esther G.C. Troost Eur Respir Monogr 2015; 68: 178-185 | |
Chemotherapy Adam Januszewski, Sanjay Popat Eur Respir Monogr 2015; 68: 186-201 | |
Systemic treatment of elderly patients Charlotte Leduc, Elisabeth Quoix Eur Respir Monogr 2015; 68: 202-214 | |
Achievements in targeted therapies Paolo Bironzo, Teresa Mele, Silvia Novello Eur Respir Monogr 2015; 68: 215-233 | |
Can we expect progress from targeted therapy of SCLC? Nevin Murray, Krista L. Noonan Eur Respir Monogr 2015; 68: 234-246 | |
Immunotherapy Niels Reinmuth, David F. Heigener Eur Respir Monogr 2015; 68: 247-260 | |
Perspective of a pulmonologist: what might we expect and what do we need to know? Nicolas Guibert, Elise Noel-Savina, Julien Mazières Eur Respir Monogr 2015; 68: 261-273 | |